Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Skip to main content
VABYSMO is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
.
Vial Prescribing Information
Pre-Filled Syringe Prescribing Information
Dose with confidence in nAMD, DMO and macular oedema secondary to RVO
The posology of VABYSMO
Explore VABYSMO's dosing flexibility across all indications, including the updated guidance that simplifies the transition for patients switching from other intravitreal anti-VEGF therapy.
Prescribing information can be found using the buttons at the top of this page.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.
